• Price of zinc recently rose to $3,369 per metric ton, reaching highest point in more than a decade
• Estimated recovery rate of 95% for zinc seen at the Blue Moon site a key catalyst to its future development
• CEO Patrick McGrath calls the site “one of the best near-term development assets” in zinc mining

For Blue Moon Zinc Corp. (TSX.V: MOON) (OTC: BMOOF), the best may be yet to come. As zinc continues to rise in value, hovering near $3,369 per metric ton at time of writing (http://dtn.fm/N6uUg), the company is focused on its Blue Moon Project, located in Mariposa County, California. Zinc is used widely, largely in the manufacture of batteries and auto parts, but it has the future potential to be used in zinc-based batteries for electric cars and other energy storage applications.

Patrick McGrath, CEO, was originally just a shareholder of the junior zinc development company, but he said in a recent interview (http://dtn.fm/z8lKS) that he saw in Blue Moon, “one of the best near-term development assets” in zinc mining. He added that prior mid-tier mining companies had already done “most of the heavy lifting for us.” The project remained dormant after early work on the site for a number of reasons, most notably low zinc prices, but BMOOF estimates that there are some 377 million pounds of zinc indicated in the project and 395 million pounds inferred at the site, citing a recently completed mineral resource estimate (http://dtn.fm/IycK8).

Another reason other mining companies were reluctant to become involved in the site was California’s reputation for being “tough” in granting mining permits, but McGrath said that obtaining project permits within that state is no tougher than elsewhere, effectively “leveling the playing field.” A high estimated recovery rate of 95% for zinc at Blue Moon’s site is key to the company’s future development, McGrath said. The Blue Moon deposit is located on 525 acres in the foothills of the Sierra Nevada Mountains.

Although the market cap for the company is just $4.7 million, McGrath described BMOOF as being a great long-term investment for several reasons. One is its robust short-term “catalyst” in the next three months: its projected 1Q18 Preliminary Economic Assessment (PEA). The company said the PEA for the site would show its potential for economic development. The PEA, according to McGrath, should indicate Blue Moon as a viable stand-alone project. Next, the Blue Moon deposit is a volcanic massive sulphide (VMS) deposit, which are often found in ‘pods,’ indicating that more zinc deposits may be nearby.

McGrath said he sees a “high likelihood” that the Blue Moon project will offer an upside prospect for investors seeking exposure to zinc.

For more information, visit the company’s website at www.BlueMoonMining.com

Let us hear your thoughts: Blue Moon Zinc Corp. Message Board

• Technology improves absorption of cannabidiol and bioactive compounds into the bloodstream
• It is now being used on all non-psychoactive cannabinoids and applied to edibles and health food products
• Patents have been awarded in the U.S. and Australia and are pending in 44 countries

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) is a biosciences company that has developed delivery technologies to improve absorption of bioactive compounds. Its patent-protected technology has improved the ability of cannabinoid-products companies to deliver active ingredients to the body. With patents pending for tetrahydrocannabinol and other psychoactive cannabinoids (plus nicotine and non-steroidal anti-inflammatory drugs), the current technology is already being applied to the use of non-psychoactive cannabinoids. This innovation has yielded a high absorption hemp oil formula that is a source of omega and fatty acids.

The health benefits of the technology and the products it has enabled are many. Lexaria has developed a product that can reduce anxiety and stress, increase mental focus and boost physiological performance and recovery. It can reduce pain and inflammation as well, while acting as a vasodilator to improve circulation.

Improved bioabsorption and lowering the cost of edibles are not the only perks of LXRP’s technology. The boost to the product market, and to investors, is already being felt. Avoiding the need for inhalation or co-administering CBD with sugars or sweeteners, the technology accelerates intestinal absorption. This has enabled the development of protein energy bars for sports nutrition and chewable CBD tablets with no sugar. Hemp oil capsules in the TurboCBD™ brand (with American ginseng and Ginkgo biloba) and teas have also been developed.

Lexaria’s technology works by masking the taste of cannabinoids as they’re consumed. It also protects the bioactive ingredients as they pass through the stomach and increases bioabsorption in the intestines by 5–10X. This rate is about equal to that of inhalation, offering a viable alternative to smoking. Onset times are also reduced. Effects may be felt with 15–20 minutes, in contrast to up to two hours via other means.

The patent awarded to LXRP for the delivery of all non-psychoactive cannabinoids makes Lexaria the first company in the world to achieve this accomplishment. Awarded in the U.S. and Australia, it is now pending in 44 other countries while supporting research and development on cannabinoids across the industry. The company has filed 19 patent applications in the U.S. and internationally. It also expects additional patent acceptances and issuances in 2017 and over the coming years.

In fact, Lexaria has out-licensed the technology as part of its royalty business model, allowing third-party partners and distributors to profit and support their own developments. The numerous deals already signed include those in various state markets, including California, Colorado and Nevada, and a distribution agreement for CBD chewables in Japan and South Korea. Lexaria’s first royalty agreement was with a fast-growing startup, but current negotiations are with larger, more established enterprises. Lexaria is expanding its global reach and expects to continue seeing growth in business deals in broader industry sectors with more well-known consumer brands.

For more information, visit the company’s website at www.LexariaEnergy.com

Let us hear your thoughts: Lexaria Bioscience Corp. Message Board

• Global alternative fuel and hybrid vehicle market projected to reach $819 billion by 2024
• Demand for alternative fuel vehicles is increasing worldwide
• Clean, cost-efficient commercial trucks are a booming market as more companies go green

Greenkraft, Inc. (OTCQB: GKIT), a California-based manufacturer of alternative fuel automotive products including engines and commercial trucks, offers eco-friendly trucks that are reliable, cost-effective and versatile. This rapidly growing sector of the automotive industry is demanding cleaner, more fuel-efficient models utilizing alternative fuels. Greenkraft’s new line of larger trucks, powered by the alternative fuels CNG and LPG in classes 4, 5, 6 and 7, provide an option for businesses seeking to have less of an impact on the environment while saving money.

The global alternative fuel and hybrid vehicle market, valued at $318 billion in 2016, is expected to reach $819 billion by 2024, recording a compound annual growth rate of 12.8 percent, according to a September 2017 Esticast Research & Consulting report (http://dtn.fm/9pNcT). Advancements in alternative fuel technologies, increasing interest in eco-friendly vehicles and an upsurge in government initiatives are expected to help push the industry forward.

One major player in the trucking industry, UPS, announced in June that it would add more alternative fuel and advanced technology vehicles to its fleet while increasing its reliance on renewable energy sources. The company set a goal that, by 2020, one in every four vehicles purchased annually for its ground fleet would be an alternative fuel or advanced technology vehicle (http://dtn.fm/KDm7R).

This move toward using more diverse and sustainable energy sources is being embraced by smaller companies and a variety of industries, as well. Earlier this year, Greenkraft successfully debuted an alternative fuel truck at the WWETT Show 2017 held in Indiana. CEO George Gemayel said the truck was well received by members of the septic tank sector of the trucking industry, noting Greenkraft’s entry into the specialized truck market could generate millions more in revenue (http://dtn.fm/G1fwZ).

Each product produced by Greenkraft provides environmentally friendly solutions to the increasingly difficult problems associated with using traditional fuels. While most vehicles across the United States are powered by either gasoline or diesel, Greenkraft manufactures and markets alternative fuel systems to convert these engines to function on natural gas and propane fuels. The company’s fuel-efficient trucks not only save businesses money, but avoid pumping tons of greenhouse gasses into the atmosphere – and that’s a win-win for any industry.

For more information, visit the company’s website at www.GreenkraftInc.com

Let us hear your thoughts: Greenkraft, Inc. Message Board

• Diversified portfolio of 300+ mobile gaming titles with hundreds of millions of players
• Full-Featured Game revenues expected to increase more than 200% in 2017 with launch of new games and other mobile entertainment updates
• Worldwide mobile gaming revenue projected to reach $74.6 billion by 2020 with mobile advertising revenue topping $166 billion by 2018

Tapinator, Inc. (OTCQB: TAPM) is a developer and publisher of mobile games on the iOS, Google Play and Amazon platforms. The Company’s portfolio includes over 300 mobile gaming titles generating hundreds of thousands of daily player downloads that provide predictable and attractive returns through the sale of branded advertisements and consumer app store transactions. Tapinator, based in New York and with product development teams located throughout the world, was founded in 2013 by a visionary team that has been building mobile games and applications since 2007 and has achieved multiple successful exits.

Tapinator’s business strategy includes the creation of a select number of best-in-class Full-Featured Games, such as ROCKY™ and Solitaire Dash, which provide game players with more in-depth, unique content that supports long-term retention and generates higher investment returns. The Full-Featured Games model creates the potential for sustainable $100+ million franchise-type games that have product lifespans of at least five years. Tapinator uses a proprietary set of dynamic development and marketing processes factored upon gaming category, estimated player retention and projected player profitability.

Recent successful launches of two new Full-Featured titles – Big Sport Fishing 2017 and Dice Mage 2 – were recognized on the Apple iOS platform as “New Games We Love.” During the game’s first seven days after global release, Big Sport Fishing 2017 received well over 520,000 player downloads. Four new titles, ColorFill, Divide & Conquer, Shadowborne and Fusion Heroes, are in the pipeline for release in Q4 2017 and Q1 2018 as well. The formula for these game combines proven gameplay elements with best-in-class monetization systems, supplemented by Tapinator’s strong creative team of developers, strategists and product specialists. The company’s Rapid-Launch Games division also saw increasing player interest recently with the launch of Fidget Spinner Superhero and Scary Shark Evolution 3D.

Tapinator’s diversified revenue sources includes 54 percent from advertising placed within its mobile games and 46 percent from consumer app store purchases. The Company limits advertising placements to between game levels and also runs rewarded video ad units that are tied directly into the game’s currency. Tapinator’s portfolio includes more than 300 active titles, with no single game accounting for more than 25 percent of total revenues during the first half of 2017.

As Tapinator looks toward the future, opportunities in Virtual Reality (VR) and Augmented Reality (AR) show great promise. The company has released several prototype VR games to gather data before pursuing a more significant VR product. Recent market reports suggest that the VR industry will hit $30 billion by 2020 and the AR industry will surpass that with a projected $120 billion. Tapinator also plans to pursue publishing transactions that leverage its network, platform relationships and operational excellence. Significant opportunities for expanding Tapinator’s gaming IP to new platforms such as Steam and leading messaging apps are also on the horizon. The company is targeting a 30+ percent annual bookings growth target for 2017-2019.

For more information, visit the company’s website at www.Tapinator.com

Let us hear your thoughts: Tapinator, Inc. Message Board

• Forbes predicts medical marijuana sales to reach $13.3 billion by 2020
• Biotech/pharma market could surpass $20 billion by 2020, per estimates from Viridian Capital Advisors
• InMed’s biosynthesis process uses DNA and E. coli to produce cannabinoids that are identical to the 90+ found in nature
• The company’s pipeline drugs, focusing on rare dermatological diseases, glaucoma and topical pain treatments, are advancing toward clinical trials

There may be many companies exploring cannabinoid biosynthesis, but one in particular stands out. InMed Pharmaceuticals (CSE: IN) (OTCQB: IMLFF) has created a revolutionary process that is poised to impact the cannabinoid market. It’s just one of several companies mentioned in a recent industry article (http://dtn.fm/5OP0a) that are actively engaged in the race to synthesize the 90+ known cannabinoids in their natural forms.

InMed’s process involves using the genetic material of naturally occurring cannabinoids. By introducing their DNA in a controlled laboratory setting, scientists can create compounds that are identical to those found in nature. Each cannabinoid has the same chemical makeup as its natural counterpart. The difficult, expensive and time-consuming challenges of planting, growing and harvesting cannabis, and then extracting the individual cannabinoids for medical use, are greatly diminished. Biosynthesis also eliminates the need for fertilizers and pesticides that can be toxic to people and harmful to the environment.

Cultivating cannabis plants also requires a great deal of manpower, not to mention resources such as electricity and water. Biosynthesis not only promises to reduce the time and effort required to extract cannabinoids; it also has the potential to expedite drug development. InMed’s approach in this area was highlighted in a recent article (http://dtn.fm/Um29W) in which its E. coli-based biosynthesis platform and the potential ability to tap into the medial benefits of every cannabinoid are noted. The E. coli-based expression system utilizes an optimized gene construct to maximize production.

The company is exploring the potential in the dermatology field for its INM-750 drug candidate for epidermolysis bullosa. Cannabinoids have shown positive results in pre-clinical testing, addressing the major hallmarks of the disease, including wound healing, pain, itch, inflammation and antimicrobial control. Of particular note are the encouraging results that show INM-750 as having the potential to modulate keratin levels, which, if successful, may modulate the course of the disease itself, a game changer for patients and for the company. InMed is also conducting testing for its ocular treatment, INM-085 for glaucoma, and pain therapy with INM-405. Capable of reducing intra-ocular pressure and protecting nerve cells and tissues in the eye, INM-085 has a proprietary delivery system, a hydro-gel, that has been engineered as a specific delivery vehicle for ocular disease.

However, the company isn’t only being touted for its biosynthesis process and drug development. It has also developed a proprietary bioinformatics system. This computer-based drug/disease targeting tool enables researchers to identify cannabinoids suitable for treating specific conditions based on drug structures, protein-protein interactions, gene regulation, cell signaling and other biological processes. This approach has been validated in advanced pre-clinical models of disease for InMed’s several development programs.

The company’s research focus extends beyond skin, eye and pain treatments. It is also studying the potential effects of cannabinoids on nervous system disorders such as Huntington’s disease. Cannabinoid research is taking place at several institutions in respiratory science, with ongoing studies into possible asthma and chronic obstructive pulmonary disease therapies. Other advances in cannabinoid science include the potential for treating diabetes, obesity and other metabolic conditions. Thus, InMed’s biosynthesis process may play an integral role in advancing drug development both internally and with other entities by making specific compounds readily available for research and commercialization.

For more information, visit the company’s website at www.InMedPharma.com

Let us hear your thoughts: InMed Pharmaceuticals, Inc. Message Board

• LTTGF names actor William Shatner as media spokesperson and Kevin Harrington, an original Shark on TV’s Shark Tank, as board member
• Company is an online lottery messenger service designed to disrupt the $70-80 billion U.S. lottery market
• Company goal is to grow to nearly $50 million annually by 2020 on a paid subscriber base of approximately 500,000 as it expands to 22 more states from its California base

LottoGopher Holdings Inc. (OTCQB: LTTGF) (CSE: LOTO) (FRA: 2LG) provides online services to lottery consumers. By naming celebrity actor William Shatner as its spokesperson and Shark Tank original Kevin Harrington to its board, the company is using celebrity connections/endorsements as a proven strategy to grow, helping to drive its plans to expand into more states and increase its share of the $70-80 billion U.S. lottery market.

LTTGF acts as a lottery messenger service that enables its customers to buy tickets for state lotteries online with credit or debit cards. The company currently operates only in California, which itself has a $6.3 billion lottery market, but it is already planning to expand into 22 more states as it moves to become national.

A new 30-second TV ad with William Shatner (http://dtn.fm/quJK4) illustrates the simplicity of using LottoGopher while disparaging the practice of waiting in line at a store to buy tickets. LTTGF’s goals by 2020 are annual sales of nearly $50 million on a paying subscriber base of approximately 500,000 as it grows into 22 more states from its current base in California (http://dtn.fm/AjeL8). In a recent news release, James Morel, president and CEO of the company, added, “In the past few months we have seen an uptick in subscriptions and we want to continue this momentum.”

A recent article points out how celebrity endorsements are a proven winning strategy utilized by companies to gain awareness, loyalty and, ultimately, market share through higher revenues (http://dtn.fm/C1MBq). Weight Watchers International, Inc. (NYSE: WTW) is associated with Oprah Winfrey, Johnson & Johnson (NYSE: JNJ) and The Coca-Cola Company (NYSE: KO) named actress Jennifer Aniston as the face of their Aveeno and Smartwater brands and Diageo PLC (NYSE: DEO) named Sean “Diddy” Combs as spokesperson and joint venture partner.

Weight Watchers became associated with celebrity Oprah Winfrey in 2015 when she purchased 10% of the company’s shares. In December 2016, Weight Watchers shares skyrocketed 16% when she starred in a new ad campaign for the company. Sean “Diddy” Combs joined British multinational alcoholic beverage company Diageo PLC as its joint-venture partner and spokesperson in 2007, before signing a subsequent deal in 2014. In that time, Diageo’s stock has soared from $91.75 in 2007 to $132.13 today.

LottoGopher hopes to see similar success. Shatner (http://dtn.fm/5Id9E), best known for his role in Star Trek, adds, “Much like Netflix disrupted the movie rental business, and Uber hailing a cab, LottoGopher is disrupting the lottery industry for Americans. Consumers nowadays demand exceptional service, competitive pricing, and the convenience of buying products online.”

LTTGF enables paying subscribers the ability to purchase Powerball, Mega Millions and SuperLotto Plus tickets online for no additional fees. The company permits players to use digital currencies, such as bitcoin. The service offers players not only the physical line-free efficient purchase of tickets, but also lucky numbers and the latest lottery news. Individuals have the option to play alone or join online groups to pool tickets and share the winnings.

In using the paid subscription model to grow its base, LTTGF also offers a free purchase of a lottery ticket to new players so that they can try out the system. Players can purchase a single day, monthly, or yearly pass to the site. Former Shark Harrington told online site Benzinga the service is the “Uber Eats” of lotteries (http://dtn.fm/6Aw04). “LottoGopher will be using TV, radio, digital media, celebrity endorsements … all the resources that are available,” he said.

Together, LTTGF’s successful business model and its move to utilize the proven marketing strategy of celebrity endorsements, represent a one-two punch for the rapidly growing lottery market.

For more information, visit the company’s website at www.LottoGopher.com

Let us hear your thoughts: LottoGopher Holdings Inc. Message Board

Ever at the forefront of Canada’s cannabis market, ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) was among the very first companies to obtain a cannabis production license in that country and has since been working to change the face of medical cannabis—both in Canada and globally. ABcann’s group of companies is working toward the aim of becoming the first cannabis pioneers to produce repeatable, standardized, plant-based medicines around the world.

Every variable of ABcann’s cannabis growing, curing and harvesting process is computer-monitored and controlled. This high-tech indoor growing environment consistently yields a superior product that is clean, steady and repeatable—something desired by every doctor and patient.

Though medical marijuana has been nationally legal in Canada since 2001, the requirements and process for growers to obtain licenses are very stringent, resulting in only about three percent of applying cannabis growers successfully obtaining a license. Canada’s government is also now working toward federally legalizing recreational marijuana, and, as discussed in a recent article (http://dtn.fm/t4ZMS), this push, coupled with the dearth of licensed growers, could eventuate in a nationwide cannabis shortage as production fails to keep pace with demand. ABcann is scaling up its operations in anticipation of this supply dearth.

There are currently, according to data from the Government of Canada (http://dtn.fm/2cVJu), only 62 licensed cannabis growers in the entire country. With blanket legalization looming on the horizon, demand is sure to increase, and ABcann is well-positioned to profit.

Focused on scaling its operations and distinguishing itself through its proprietary organic and pesticide-free growing technology, ABcann has been making strategic strides in recent months. The company recently announced the receipt of $11.9 million in proceeds from the exercise of warrants. Combined with a previous investment from Cannabis Wheaton Income Corp., this brought ABcann’s cash position to about $45 million, and, in the coming months, the company intends to deploy capital toward expanding its existing Vanluven facility and in developing and constructing its new Kimmett facility. The company will further pursue international expansion plans.

Led by an experienced management team and advisory board, ABcann boasts an impressive production yield that has put it at the vanguard of this highly competitive market.

For more information, visit the company’s website at www.ABcann.ca

Let us hear your thoughts: ABcann Global Corp. Message Board

• Focused on developing remedies from cannabis oil
• Research programs in conjunction with Universities of Waterloo & Western Ontario
• Strategy to capture market share of non-smoke MMJ nutraceuticals

To acquire the benefits of cannabis, there are many pathways, with some being distinctly safer than others. There are tinctures and topicals; there is dabbing; and there is vaping. There are drinks and digestibles and, of course, there is smoking. Over the last few decades, what some wits refer to as ‘puffing the magic dragon’ has emerged as the top delivery method for users of cannabis, but smoking harms nearly every organ of the body and causes many diseases, according to the Centers for Disease Control (CDC) (http://dtn.fm/eZ5Tg). Given such adverse aftereffects, interest in safer delivery options, like those made possible by technology from Algae Dynamics Corp. (OTC: ADYNF), has grown. Algae Dynamics is an innovative biotech currently engaged in the development of nutraceuticals and pharmaceuticals utilizing hemp, cannabis and algae oils. The company plans to be a global leader in the formulation and development of health products from cannabis derivatives, algae oils and other botanical oils.

The days when inhaling and exhaling tobacco fumes was regarded as chic or sophisticated are long gone. Now that the danger from cigarettes has been laid bare, the glamour long associated with them has evaporated much as their smoke does. Smoking is responsible for about 480,000 deaths each year in the United States; that is nearly one in five deaths, a figure that exceeds the combined fatalities due to HIV, illegal drug use, alcohol, motor vehicle accidents and gun-related incidents. Notably, ‘more than 10 times as many U.S. citizens have died prematurely from cigarette smoking than have died in all the wars fought by the United States’, according to the U.S. Surgeon General (http://dtn.fm/I0LlZ). These compelling statistics, together with government and private initiatives, have raised awareness of the threats posed by smoking, which extend not only to the use of tobacco but also to the newly emerging therapeutic treatments based on cannabis.

In response to the imperative for safer delivery of cannabinoids, Algae Dynamics has been working with two of Canada’s leading research universities – the University of Western Ontario and the University of Waterloo. This collaborative research is focused on the use of extracts from cannabis oil to treat some mental health issues and various forms of cancer. The program at the University of Western Ontario is studying the effects of cannabis oil on depression, post-traumatic stress disorder (PTSD), anxiety and schizophrenia, while research at the University of Waterloo is examining ways of treating colorectal, pancreas, breast and prostate cancers.

To support these research efforts, Algae Dynamics announced in August 2017 that it would be collaborating with Bonify, a Licensed Producer (LP), under the Access to Cannabis for Medical Purposes Regulations (ACMPR) in Canada, to engage in the extraction of cannabis oil, according to MarketWatch (http://dtn.fm/7yhMW). The joint initiative entails the purchase and installation of cannabis oil extraction equipment by ADYNF at Bonify’s facility in Winnipeg, Canada. This deal will secure cannabis material for extraction and will generate revenue. As well, the cannabis oil thus produced will be supplied to the University of Waterloo and University of Western Ontario to support the Sponsored Research Agreements that ADYNF has in place with the two universities.

The market for cannabis oil is still in its embryonic stage, but it is likely to grow quickly, spurred by recent trends. A 2016 Mackie Research Capital report, extrapolating data from Colorado, one of the first U.S. states to legalize marijuana, estimates that 45 percent of dried marijuana users would eventually convert to marijuana extracts and/or oils. New Cannabis Ventures even billed cannabis extracts as ‘The Next Canadian Oil Boom’ (http://dtn.fm/I4ZRn) after a court ruling allowing LPs to produce cannabis extracts. The Canadian cannabis oil extraction market is projected to grow to C$1.7 billion by 2020. With legalization for recreational use set for July 2018, safer delivery routes for cannabis therapeutics like those engineered by Algae Dynamics are sorely needed to help customers and patients avoid the hazards of smoking.

For more information, visit the company’s website at www.AlgaeDynamics.com

Let us hear your thoughts: Algae Dynamics Corp. Message Board

• Rapidly expanding network of analytical cannabis testing laboratories now serving five states
• Accurate, reliable lab results based on scientific principles using state-of-the-art facilities
• Analytical services include testing cannabis flowers, extracts and infused products

EVIO, Inc. (OTCQB: EVIO), via the EVIO Labs division, is the nation’s leading provider of accredited analytical testing, scientific research and advisory services to the regulated cannabis industry. EVIO Labs provides state-mandated ancillary services that are required to ensure the safety and quality of the nation’s cannabis supply. EVIO Labs has performed over 50,000 tests during the past two years and grown from one laboratory in Oregon to nine labs spanning California, Oregon, Colorado, Massachusetts and Florida.

EVIO Labs is driving the cannabis testing industry by providing clients nationwide with consistent high-quality cannabis analytical services backed by quality control assurances. The company also provides advisory services that help cannabis producers and retailers enhance production processes, achieve regulatory compliance and meet quality goals.

EVIO Labs is on track to open 18 laboratories by the end of 2018 at locations around the United States. The Oregon-based company provides analytical services that include testing cannabis and industrial hemp flower, extracts and infused products. The labs specialize in performing the following tests:

• Cannabinoid analysis, which properly characterizes the many primary cannabinoids found in cannabis including THC, CBD, and several other cannabinoids.
• Terpene analysis, which identifies the aromatic compounds of the plant (terpene), which can help identify the therapeutic potential of a cannabis flower or extract.
• Moisture content and water activity, which measure the moisture levels of dried cannabis and are indicators of microbiological growth potential.
• Pesticide residue analysis of over 100 different pesticides, herbicides, fungicides, growth regulators and other agrochemicals that may be present on cannabis.
• Detection of harmful residual solvents left behind in the cannabis extract production process.
• Microbial testing screen for bacterial and fungal contamination in cannabis and cannabis-infused products.
• Detection of heavy metals including lead, cadmium, mercury, and arsenic.

EVIO Labs is rapidly becoming the nation’s leading cannabis biotechnology company. Led by a management team with extensive experience in designing and rolling out successful business ventures, product research and development, regulatory and compliance protocols, medical cannabis cultivation, production and analytical chemistry techniques, EVIO Labs is prepared to take advantage of today’s fastest growing industry.

For more information, visit the company’s website at www.EVIOLabs.com

Let us hear your thoughts: EVIO, Inc. Message Board

• Patented technology enhances how topical and transdermal drugs and skin care products are delivered
• Polymer delivery vehicle can be tailored to almost any type of molecule including the medicinal components of hemp and marijuana
• 14 patents granted in the U.S. and internationally
• $65 billion market in dermatology, pharmaceutical and other healthcare industries offers strong growth opportunity

Skinvisible, Inc. (OTCQB: SKVI), through its wholly owned subsidiary Skinvisible Pharmaceuticals, Inc., is a Research and Development company whose patented Invisicare® technology can be used to revitalize or create new medical or skincare products, allowing a company that licenses Skinvisible’s formulations to sell their own patented product and combat generic competitors.

A prescription dermatology product can generate $100 million or more a year, with the potential to lose 50-90% of that revenue when it goes off patent. Preserving that revenue is why the licensing of a product made with Invisicare is a very desirable option for many companies. The Company has developed a pipeline of 40 products using Invisicare, with a primary focus on optimizing the performance and increasing the value of “gold standard” dermatology drugs and licensing them to international and multi-national companies in the pharmaceutical, over-the-counter and cosmeceutical markets.

Invisicare® is a high performance topical and transdermal delivery system which enhances the delivery of drugs and other ingredients to and through the skin. The key to Skinvisible’s patented technology and trademarked Invisicare® family of polymer delivery vehicles is its formula and process for combining hydrophilic and hydrophobic polymers into stable complexes in water emulsions. Invisicare® can be a key component of life cycle management, extending the life with a new patent-protected product, dramatically expanding the company’s revenue stream.

Independent studies of Invisicare ® have shown the following benefits:

• Active ingredients stay on the skin for up to four hours or more and resist wash off and rub off.
• Delivery method results in improved efficacy, reduced skin irritation and lower required dosage.
• Unique formulations are non-drying and provide the ability to control the release of active ingredients.
• Products form a protective barrier, which means normal skin respiration and perspiration occur and the product wears off as part of the skin’s natural exfoliation process.

Terry Howlett, President, founder and CEO of Skinvisible Inc., said the Company has more than 15 years of scientific research and product development experience. All development is conducted using stringent pharmaceutical standards. The Company has licensed a number of its formulations including a prescription hemorrhoid cream in the USA, its anti-aging Kintari® line of products and DermSafe®, its non-alcohol hand sanitizer to a licensee in China. Producing licensed products for the booming cannabis industry is also an important element of the company’s business strategy.

Skinvisible’s foray into the rapidly expanding market for medicinal and recreational cannabis products is already underway with the development of the company’s first hemp-derived CBD (cannabidiol) products. Skinvisible has negotiated an exclusive licensing deal in Canada with Canopy Growth Corporation, one of the world’s leading cannabis companies. As part of the company’s overall growth strategy, Skinvisible is also negotiating with a Licensed Producer in Las Vegas where Skinvisible scientists will develop THC (tetrahydrocannabinol) products for the legal recreational and medical marijuana market for the USA. Notably, Skinvisible is actively pursuing potential licensees through-out the world where medical cannabis is legal. These licensees will have the exclusive right to manufacture and distribute Skinvisible’s cannabis products within their territory.

“We are excited about the results we are already seeing just with our hemp-derived CBD products,” Howlett says. “Our science shows that our CBD products release almost four times that of market leaders and our transdermal product had an 81% penetration rate at 6 hours. These results are significant and provide the difference between ordinary cannabis products and ones enhanced by Invisicare.”

The Company’s business model includes out-licensing its formulations for a development fee, license fee and on-going royalties in addition to selling its Invisicare polymers to its licensees.

For more information, visit the company’s website at www.Skinvisible.com

Let us hear your thoughts: Skinvisible, Inc. Message Board